1. Walsh G. Modern antibody based therapeutics. Biopharm 2004; Dec.: 18-25.

2. Cochlovius B, Braunagel M, and Welschof M. Therapeutics antibodies. Mod. Drug Discov. 2003; 6: 33-38.

3. Stockwin LH and Holmes S. Antibodies as therapeutic agents: Vive la renaissance! Expert Opin. Biol. Ther. 2003; 3: 1133-1152.

4. Djik MA van, Winkel J, and GJ van de. Human antibodies as next generation therapeutics. Curr. Opin. Chem. Biol. 2001; 5: 368-374.

5. Lo BKC. Review: Antibody humanization by CDR grafting. Meth. Mol. Biol. 2004; 248: 135-159.

6. Rohrbach P, Broders O, Toleikis L, and Stefan D. Therapeutic antibodies and antibody fusion proteins. Biotechnol. Genet. Eng. Rev. 2003; 20: 137-163.

7. Jefferis R. CCE IX: Review. Glycosylation of recombinant antibody therapeutics: relevance to therapeutic applications. Biotechnol. Prog. 2005; 21: 11-16.

8. Goding JW. Monoclonal Antibodies: Principles and Practice. London: Academic Press, 1983.

9. Aruffo A. Immunoglobulin fusion proteins. In: Chamow S and Ashkenazi A, Eds. Antibody Fusion Proteins. NY: Wiley-Liss, 1999, pp. 221-241.

10. Keller K, Friedmann T, and Boxman A. The bioseparation needs for tomorrow. Trends Biotechnol. 2001; 19: 438-441.

11. Myers J. Economic consideration in the development of downstream steps for large-scale commercial biopharmaceutical processes: Production and Economics of Biopharmaceuticals conference, San Diego, November, 2000.

12. Wheelright SM. Protein Purification: Design and Scale-up of Downstream Processing. Munich (Germany): Hanser, 1991.

13. Naveh D and Siegel RC. Large-scale downstream processing of monoclonal antibodies. Bioseparation 1991; 1: 351-366.

14. Ostlund C. Large-scale purification of monoclonal antibodies. Trends Biotechnol. 1996; 166: 288-293.

15. Gagnon P. Protein A affinity chromatography. In: Purification Tools for Monoclonal Antibodies. Tucson, AZ: Validated Biosystems, 1996, pp. 155-158.

16. Follman D and Fahrner RL. Factorial screening of antibody purification processes using three chromatographic steps without Protein A. J. Chromatogr. A 2004; 1024: 79-85.

17. Fahrner RL, Knudsen H, Basey C, Galan W, Feuerhelm D, Vanderlaan M, and Blank G. Industrial purification of pharmaceutical antibodies: Development, operation and validation of chromatography processes. Biotechnol. Genet. Eng. Rev. 2001; 18: 301-327.

18. Blank G. The future of process development for monoclonal antibody manufacturing. IBC Conference on Antibody Production and Downstream Processing, San Diego, CA, March, 2005.

19. Hubbard BH and Shukla AA. Platform approaches to monoclonal antibody purification. IBC Conference on Antibody Production and Downstream Processing, San Diego, CA, March, 2005.

20. Hjelm H, Sjodahl J, and Sjoquist J. Immunologically active and structurally similar fragments of protein-A from Staphylococcus aureus. Eur. J. Biochem 1975; 57: 395-403.

21. Sjoquist J. Structure and immunology of protein A. Contrib. Microbiol. Immunol. 1972; 1: 83-92.

22. Moks T, Abrahmsen L, Nilsson B, Hellman U, Sjoquist J, and Uhlen M. Sta-phylococcal protein-A consists of five IgG-binding domains. Eur. J. Biochem 1986; 156: 637-643.

23. Hjelm H, Hjelm K, and Sjoquist J. Protein A from Staphylococcus aureus. XXIII. Its isolation by affinity chromatography and its use as an immunosorbent for isolation of immunoglobulins. FEBS Lett. 1972; 28: 73-76.

24. Kronvall G. Surface component in group A, C, and G streptococci with nonimmune reactivity for immunoglobulin G. J. Immunol. 1973; 111: 1401-1406.

25. Diesenhofer J, Jones TA, Huber R, Sjodahl J, and Sjoquist J. Crystallization, crystal structure analysis and atomic model of the complex formed by a human Fc fragment and fragment B of protein A from Staphylococcus aureus. Hoppe-Seyler's Z. Physiol. Chem. 1978; 359: 975-985.

26. Diesenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Sta-phylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry 1981; 20: 2361-2370.

27. Li R, Dowd V, Stewart D, Burton SJ, and Lowe CR. Design, synthesis and application of a Protein A mimetic. Nat. Biotechnol. 1998; 16: 190-195.

28. Cedergren L, Andersson R, Jansson B, Uhlen M, and Nilsson, B. Mutational analysis of the interaction between staphylococcal protein A and human IgG1. Protein Eng. 1993; 6: 441-448.

29. Burton DR. Immunoglobulin G: functional sites. Mol. Immunol. 1985; 22: 161-206.

30. Lindmark R, Movitz J, and Sjoquist J. Extracellular protein A from amethicillin-resistant strain of Staphylococcus aureus. Eur. J. Biochem. 1977; 74: 623-628.

31. Bywater R, Eriksson GB, and Ottosson T. Desorption of immunoglobulins from Protein A-Sepharose CL-4B under mild conditions. J. Immunol. Meth. 1983; 64: 1-6.

32. Inganas M. Comparison of mechanisms of interaction between protein A from Staphylococcus aureus and human monoclonal IgG, IgA and IgM in relation to the classical Fcy and the alternative F(ab) protein A interactions. Scand. J. Immunol. 1981; 13: 343-352.

33. Vidal MA and Conde FP. Alternative mechanism of Protein A — immunoglobulin interaction: The VH associated reactivity of a monoclonal human IgM. J. Immunol. 1985; 135: 1232-1238.

34. Akerstrom A, Nilson Bo HK, Hoogenboom HR, and Bjorck L. On the interaction between single chain Fv antibodies and bacterial immunoglobulin-binding proteins. J. Immunol. Meth. 1994; 177: 151-163.

35. Starovasnik MA, O'Connell MP, Fairbrother WJ, and Kelley RF. Antibody variable region binding by Staphylococcal Protein A: Thermodynamic analysis and location of the Fv binding site on E-domain. Protein Sci. 1999; 8: 14231431.

36. Sasso EH, Silverman GJ, and Mannik M. Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup. J. Immunol. 1991; 147: 1877-1883.

37. Sasso EH, Silverman GJ, and Mannik M. Human IgM molecules that bind staphylococcal protein A contain VHIII H chains. J. Immunol. 1989; 142: 2778-2783.

38. Tomlinson IM, Walter G, Marks JD, Llewelyn MB, and Winter G. The repertoire of human germline Vh sequences reveals about fifty groups of Vh segments with different hypervariable loops. J. Mol. Biol. 1997; 227: 776-798.

39. Ignatovich O, Tomlinson IM, Jones PT, and Winter G. The creation of diversity in the human Immunoglobulin Vx repertoire. J. Mol. Biol. 1997; 268: 69-77.

40. Walter MA and Cox DW. Analysis of genetic variation reveals human immunoglobulin VH-region gene organization. Am J. Hum. Genet. 1988; 42: 446-451.

41. Schroeder HW, Hillson JL, and Perlmutter RM. Structure and evolution of mammalian VH families. Int. Immunol. 1990; 2: 41-50.

42. Hillson JL, Karr NS, Opplinger IR, Mannik M, and Sasso EH. The structural basis of germline-encoded Vh3 immunoglobulin binding to Staphylococcal Protein A. J. Exp. Med. 1993; 178: 331-336.

43. Potter KN, Li Y, Mageed RA, Jefferis R, and Capra JD. Anti-idiotypic antibody D12 and superantigen SPA both interact with human VH3-encoded antibodies on the external face of the heavy chain involving FR1, CDR2 and FR3. Mol. Immunol. 1998; 35: 1179-1187.

44. Potter KN, Li Y, and Capra JD. Staphylococcal Protein A simultaneously interacts with Framework region 1, Complementarity-Determining Region 2, and Framework Region 3 on human VH3-encoded Igs. J. Immunol. 1998; 157: 2982-2988.

45. Huse K, Bohme HJ, and Scholz GH. Purification of antibodies by affinity chromatography. J. Biochem. Biophys. Meth. 2002; 51: 217-231.

46. Langone JJ. Protein-A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and Pneumonococci. Adv. Immunol. 1982; 32: 157-252.

47. Schuler G and Reinacher M. Development and optimization of a single-step procedure using protein A affinity chromatography to isolate murine IgG1 monoclonal antibodies from hybridoma supernatants. J. Chromatogr. 1991; 587: 61-70.

48. Tu YY, Primus FJ, and Goldenberg DM. Temperature affects binding of murine monoclonal IgG antibodies to protein A. J. Immunol. Meth. 1988; 109: 43-47.

49. Hahn R, Schlegel R, and Jungbauer A. Comparison of Protein-A affinity sorbents. J. Chromatogr. A 2003; 790: 35-51.

50. GE technical note on "Chemical and Functional Stability of a new Protein A Media with high Dynamic Binding Capacity Based on Novel, Highly Rigid Agarose Beads" (FileDownload)?0penAgent&docid=D1A8F2CE4D763D46C1256EB400417 E1F&file = 18114904AA.pdf

51. Malmquist G, Lacki KM, Ljunglof A, and Johansson H. Engineering a new generation of affinity media for antibody purification: Presentation at Prep conference, Washington D.C., May, 2003.

52. McCue JT, Kemp G, Low D, and Quinones-Garcia I. Evaluation of Protein-A chromatography media. J. Chromatogr. A 2003; 989: 139-153.

53. Lebreton B, Lazzarechi K, McDonald P, and O'Leary R. Performance evaluation of Prosep Va: an "animal-free" protein A resin. Recovery of Biological Products XI, Banff, Canada, September 2003.

54. Jungbauer A and Hahn R. Engineering protein A affinity chromatography. Curr. Opin. Drug. Discov. Develop. 2004; 7: 248-256.

55. Fahrner RL, Whitney DH, Vanderlaan M, and Blank GS. Performance comparison of Protein-A affinity chromatography sorbents for purifying recombinant monoclonal antibodies. Biotechnol. Appl. Biochem. 1999; 30: 121-128.

56. Fahrner RL, Iyer HV, and Blank GS. The optimal flow rate and column length for maximum production rate of protein A affinity chromatography. Bioprocess Eng. 1999; 21: 287-292.

57. Iyer H, Henderson F, Cunningham E, Webb J, Hanson J, Bork C, and Conley L. Considerations during development of a Protein-A based antibody purification process. BioPharm 2002; January: 14-20.

58. Shukla AA, Hinckley PJ, and Hubbard B. Productivity comparisons on Protein-A affinity chromatography. ACS National Meeting, Boston, MA, August, 2002.

59. Gottschlich N and Kasche V. Purification of monoclonal antibodies by simulated moving bed chromatography. J. Chromatogr. A 1997; 765: 201-206.

60. Thommes J, Conley L, Pieracci J, and Sonnenfeld A. Protein A affinity simulated moving bed chromatography for continuous monoclonal antibody purification. Recovery of Biological Products XI, Banff, Canada, September: 2003.

61. Fahrner RL, Blank G, and Zapata G. Expanded bed protein A affinity chromatography of a human monoclonal antibody: process development, operation and comparison with a packed bed method. J. Biotechnol. 1999; 75: 273-280.

62. Blank GS, Zapata G, Fahrner R, Milton M, Yedinak C, Knudsen H, and Schmelzer C. Expanded bed adsorption in the purification of monoclonal antibodies: a comparison of process alternatives. Bioseparation 2001; 10: 65-71.

63. Ghose S, Nagrath D, Brooks C, Hubbard B, and Cramer SM. Use and optimization of a dual flow rate loading strategy to maximize throughput in Protein A affinity chromatography. Biotechnol. Prog. 2004; 20: 830-840.

64. Chen T. Formulation concerns of protein drugs. Drug. Develop. Ind. Pharm. 1992; 18: 1311-1354.

65. Krishnamurthy R and Manning MC. The stability factor: importance in formulation development. Curr. Pharm. Biotechnol. 2002; 3: 361-371.

66. Shukla AA, Hinckley PJ, Gupta P, Yigzaw Y, and Hubbard B. Strategies to address aggregation during Protein-A chromatography. BioProcess International 2005; May: pp. 36-45.

67. Reifsnyder DH, Olson CV, Etcheverry T, and Prashad H, Builder SE. Purification of insulin-like growth factor-I and related proteins using underivatized silica. J. Chromatogr. A 1996; 753: 73-80.

68. Terman DS and Bertram JH. Antitumor effects of immobilized protein A and staphylococcal products: linkage between toxicity and efficacy, and identification of potential tumoricidal reagents. Eur. J. Cancer Clin. Oncol. 1985; 21: 1115-1122.

69. Sofer GK, and Nystrom LE. Process hygiene. In: Process Chromatography. A Practical Guide. New York: Academic Press, 1989, pp. 93-105.

70. Tejeda-Mansir A, Espinoza R, Montesinos RM, and Guzman R. Modelling regeneration effects on protein-A affinity chromatography. Bioprocess Eng. 1997; 17: 39-44.

71. Millipore technical note # TB1021EN00 on "Cleaning ProSep®-A Protein A Affinity Chromatography Media", docs/66lllf (accessed September 2005).

72. GE Heathcare technical note No. 18117765 on "The use of NaOH for CIP of rProtein A media: a 300 cycle study". http://www.bioprocess. D97005AAF4F/$file/18117764AA.pdf (accessed September 2005).

73. GE Heathcare technical note No. 11-0011-64 AA on "MabSelect SuRe — studies on ligand toxicity, leakage, removal of leached ligand, and sanitization". OpenAgent&docid = 6127EE90B62C21F4C1256F6A000DC19C&file = 11001164AA.pdf (accessed September 2005).

74. GE Heathcare technical note No. 11-0011-65 AA on "MabSelect SuRe: alkali-stabilized Protein A derived medium for capture of monoclonal antibodies".

OpenAgent&docid = BD6F2CD251195D7BC1256F6A000DC219&file = 11001165AA.pdf (accessed September 2005).

75. Millipore technical note No. TB1650EN00 on "ProSep-vA Ultra Media 300 Cycle Lifetime Studies". tb1650en00 (accessed September 2005).

76. Duffy SA, Moellering B, Prior G, Doyle K, and Prior C. Recovery of therapeutic grade antibodies: protein A and ion-exchange chromatography. Biopharm 1989; June: 34-47.

17 Polishing Methods for Monoclonal IgG Purification

+1 0

Post a comment